HR 2113 · 116th Congress · Health

Prescription Drug STAR Act

Introduced 2019-04-08· Sponsored by Rep. Neal, Richard E. [D-MA-1]· House

Bill Progress

Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Placed on the Union Calendar, Calendar No. 571.(2020-12-24)

Plain Language Summary

[AI summary unavailable — showing source text] Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or the Prescription Drug STAR Act This bill establishes requirements for prescription drug manufacturers to provide certain information about pricing, discounts, and product samples of applicable drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to annually determine whether there are price increases of a certain threshold for outpatient prescription drugs covered under Medicare, excluding low-cost drugs. Manufacturers must provide HHS with an explanation for drug prices that (1) cumulatively increase by at least 10% or $10,000 over one year; (2) cumulatively increase by at least 25% or $25,000 over three years; or (3) are at least $26,000 annually, per individual, if first covered by Medicare during the applicable year. The manufacturer must explain the role of the factors contributing to such prices and other relevant information, including manufacturing costs, marketing costs, and revenue. Additionally, drug manufacturers must provide HHS with aggregate data related to product samples of drugs, devices, biologic products, and medical supplies given to hospitals, phys…

Summarized by Claude AI · Non-partisan · For informational purposes only

CBO Cost Estimate

Congressional Budget Office

H.R. 2113, Prescription Drug STAR Act

Jun 25, 2019

As ordered reported by the House Committee on Ways and Means on April 9, 2019

Full CBO report ↗

Official non-partisan budget analysis by the Congressional Budget Office

Cosponsors (11)

9 Democrats2 Republicans